{"id":"NCT02320396","sponsor":"Organon and Co","briefTitle":"Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)","officialTitle":"A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-09","primaryCompletion":"2015-04-27","completion":"2015-04-27","firstPosted":"2014-12-19","resultsPosted":"2016-05-30","lastUpdate":"2024-05-17"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Desloratadine 5 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Desloratadine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an efficacy and safety study of desloratadine (MK-4117) in Japanese participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that the change from Baseline in Total Nasal Symptom Score (TNSS) is improved by desloratadine compared to placebo.","primaryOutcome":{"measure":"Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy","timeFrame":"Baseline, Day 1 to Day 13 (Weeks 1 through 2 average) of double-blind treatment","effectByArm":[{"arm":"Desloratadine","deltaMin":-1.41,"sd":null},{"arm":"Placebo","deltaMin":-0.59,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":223},"commonTop":[]}}